Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA ®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding their kidney efficacy and safety. The CARMELINA ® tria...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Julio Rosenstock, Vlado Perkovic, John H. Alexander, Mark E. Cooper, Nikolaus Marx, Michael J. Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, David Baanstra, Egon Pfarr, Michaela Mattheus, Uli C. Broedl, Hans-Juergen Woerle, Jyothis T. George, Tags: Original investigation Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Study | Urology & Nephrology